Fewer than 10% of individuals who could benefit from GLP-1 drugs like Wegovy can access them, warns the global health agency as it releases its inaugural recommendations on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be addressed with thorough and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key hurdles to broad availability to the jabs that can assist patients in reducing substantial body mass, explains the body.
Skinny Jab Scarcity
Even in the present most favorable case, the manufacturing of such drugs would only suffice for around 100 million people – fewer than 10% of the global need, according to the WHO.
The guideline encourages governments and firms to expand access, through measures including patent sharing.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is due to expire in a number of nations in 2026.
How Obesity Jabs Function
The injections replicate a natural hormone to reduce digestion speed, curb appetite and enhance the sense of being full so individuals eat less.
Individuals usually begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Studies suggests patients may regain a significant portion within a year of halting the treatment, when their typical appetite resume.
Being carrying excess weight raises your chance for contracting health problems, such as type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity impacts people in all nations and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
